Cargando…

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795431/ https://www.ncbi.nlm.nih.gov/pubmed/19904263 http://dx.doi.org/10.1038/sj.bjc.6605411

Ejemplares similares

Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
por: Pursche, Stefan, et al.
Publicado: (2008)

Imatinib Mesylate plus Hydroxyurea Chemotherapy for Cerebellar Meningioma in a Belgian Malinois Dog
por: JUNG, Hae-Won, et al.
Publicado: (2014)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
por: Jain, Parveen, et al.
Publicado: (2013)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
por: Al-Amleh, Esraa K., et al.
Publicado: (2022)

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
por: Stupp, R., et al.
Publicado: (2011)

Mutagenic and Genotoxic Effect of Hydroxyurea
por: Santos, Jean L., et al.
Publicado: (2011)

Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease
por: Moreira, J. A., et al.
Publicado: (2016)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Proceedings: DNA synthesis in the presence of hydroxyurea.
por: Brown, J. S., et al.
Publicado: (1974)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults
por: Badawy, Sherif M., et al.
Publicado: (2017)

Widespread Natural Occurrence of Hydroxyurea in Animals
por: Fraser, David I., et al.
Publicado: (2015)

Synchronisation by hydroxyurea does not affect the sensitivity of CEM-C7 lymphoblasts to glucocorticoids.
por: Maehira, F., et al.
Publicado: (1984)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
por: A., CAMPOS, et al.
Publicado: (2022)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Hydroxyurea Induced Perimalleolar Ulcers
por: Saravu, Kavitha, et al.
Publicado: (2006)

Blue Lunula Related with Hydroxyurea
por: Üsküdar Teke, Hava, et al.
Publicado: (2013)

The Cell Killing Mechanisms of Hydroxyurea
por: Singh, Amanpreet, et al.
Publicado: (2016)

Hydroxyurea-induced Tooth Discoloration
por: Okuyucu, Muhammed, et al.
Publicado: (2020)

Hydroxyurea—The Good, the Bad and the Ugly
por: Musiałek, Marcelina W., et al.
Publicado: (2021)

Hydroxyurea-Induced Acute Pancreatitis
por: Bath, Harjot, et al.
Publicado: (2022)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

Further evidence supporting the global use of hydroxyurea
por: Archer, Natasha M.
Publicado: (2023)

Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma cells synchronized by centrifugal elutriation.
por: Grdina, D. J., et al.
Publicado: (1979)

Nitric Oxide Generation from Hydroxyurea via Copper‐catalyzed Peroxidation and Implications for Pharmacological Actions of Hydroxyurea
por: Sato, Keizo, et al.
Publicado: (1997)

Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
por: Rinaldi, Ikhwan, et al.
Publicado: (2019)

Melanonychia and skin hyperpigmentation with hydroxyurea therapy
por: Koley, Sankha, et al.
Publicado: (2010)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

The Use of Hydroxyurea in the Treatment of COVID-19
por: Foster, Melissa Robin Bowman, et al.
Publicado: (2021)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
por: Gohal, Gassem A, et al.
Publicado: (2022)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
por: Horne, G. A., et al.
Publicado: (2020)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Genomic mapping of single-stranded DNA in hydroxyurea-challenged yeasts identifies origins of replication
por: Feng, Wenyi, et al.
Publicado: (2006)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

P-018: MILESTONES ALONG MY PERSONAL JOURNEY WITH HYDROXYUREA
por: A., SHAKIR
Publicado: (2022)

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
por: Kelley, R K, et al.
Publicado: (2013)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial
por: Ware, Russell E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mfpgbfhp4gup8ca9arb8u1fudl